Aktie A3D5Y7 STRUCTURE THERAPEUTICS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Structure Therapeutics Inc.

Aktien

A3D5Y7

US86366E1064

GPCR

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 21.06.2024 		% 5 Tage % 1. Jan.
45.57 USD -2.52% Intraday Chart für Structure Therapeutics Inc. -5.40% +11.80%
07.06. Structure Therapeutics schließt Angebot über 547,4 Millionen Dollar ab MT
07.06. STRUCTURE THERAPEUTICS INC. : BMO Capital bekräftigt seine Kaufempfehlung ZM

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Structure Therapeutics Closes $547.4 Million Offering
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
Structure Therapeutics Prices Upsized $476 Million Stock Offering
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
Structure Therapeutics Plans Offering of American Depositary Shares
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
Top Midday Gainers
Sector Update: Health Care Stocks Edge Higher Monday Afternoon
Structure Therapeutics Reports Positive Topline Data From Obesity Trial; Shares Jump
Structure Therapeutics' obesity drug meets main goal in mid-stage study
Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
Structure Therapeutics Inc. Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290
Structure Therapeutics Inc. Announces Ramy Farid Not Standing for Re-Election to Board of Directors, Term Expire on June 25, 2024
Structure Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
ADRs Edge Higher; Lufax Climbs Almost 46%
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
Structure Therapeutics Q4 Loss Widens
Structure Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D5Y7 Aktie
  4. Nachrichten Structure Therapeutics Inc.
  5. Andere Sprachen